Novel specific CK1ε inhibitors could play an important role in the therapeutic strategy for refractory or relapsed patients with CLL and NHL, whereas CK1α specific inhibitors can be useful for MDS and some subtypes of AML. This evidence concerns the gene CSNK1A1 and non-Hodgkin lymphoma.